Significant backlash. Operating profit for the first quarter (January to March 24) of the fiscal year ending 24/12 was announced to be 2,283 billion yen, up 474.4% from the same period last year. In the pharmaceutical business, the fibrosis treatment drug Aisurui remained steady in the Chinese market. The full-year forecast remained unchanged at 16.286 billion yen, up 24.2% from the previous fiscal year. Also, in addition to preparing to apply for a market classification change to the Tokyo Stock Exchange Prime Market, it has been clarified that they have formed a business alliance with Governance Partners (Minato-ku, Tokyo) for investment fund recruitment/management.
ＧＮＩ---大幅に反発、24年12月期第1四半期の営業利益5.7倍、東証プライムへの区分変更申請準備
GNI--- significant backlash, 5.7 times operating profit for the 1st quarter of the fiscal year ending 12/24, preparation for applying for a change of classification to Tokyo Stock Exchange Prime
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.